The Gene Panel Market is becoming an increasingly important component of precision oncology and personalized healthcare. Market Research Future estimates that the global market will grow from USD 4.12 billion in 2026 to USD 14.03 billion by 2035, registering a CAGR of 14.58%. The market was valued at USD 3.56 billion in 2025.

The growing need for comprehensive cancer profiling is one of the strongest factors influencing demand. Traditional single-gene testing may provide limited genomic information, whereas multi-gene panels allow laboratories to evaluate numerous clinically relevant genes simultaneously. This capability can support cancer-risk assessment, treatment planning, hereditary disease identification, and therapeutic decision-making.

Cancer Risk Assessment was the largest application segment in 2025, accounting for 52.45% of the market. Increasing awareness of hereditary cancer syndromes and wider adoption of multi-gene testing guidelines are supporting the segment. Pharmacogenetics is also emerging as an attractive opportunity, with the segment projected to grow at a 15.11% CAGR through 2035.

The technology landscape is evolving rapidly. Amplicon-based sequencing held a 65.46% share in 2025 because it provides cost-efficient and relatively rapid workflows. Hybridization-based sequencing is expected to grow significantly as larger gene panels require improved coverage uniformity. The development of faster sequencing platforms and more efficient laboratory workflows is helping expand access to genomic testing.

Research laboratories and diagnostic providers are also benefiting from increasing automation. Testing services are projected to grow at a CAGR of 15.23% through 2035 as smaller healthcare facilities outsource complex genomic testing to specialized laboratories. This model enables providers to access advanced sequencing and bioinformatics capabilities without making substantial investments in internal infrastructure.

AI-enabled genomic interpretation is another major trend. Advanced computational tools can assist with variant classification, potentially reducing analysis time and helping laboratories manage increasing testing volumes. Integration of sequencing, bioinformatics, and clinical reporting into unified platforms is also improving workflow efficiency.

Regionally, North America led the market with 38.95% revenue share in 2025. Strong payer infrastructure, high oncology testing adoption, and established genomic medicine capabilities support regional dominance. Asia-Pacific is projected to achieve a 15.25% CAGR through 2035, supported by national genomics programs in countries including China, India, and Japan.

As genomic testing becomes increasingly embedded in cancer care and preventive medicine, the Gene Panel Market is expected to benefit from rising clinical adoption, technological improvements, and expanding applications across healthcare.